INLEXZO™
(gemcitabine intravesical system)
Connect with us
Connect with us
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INLEXZO™ (gemcitabine intravesical system)
Medical Information
INLEXZO - Use in Patients with Prior Intravesical Gemcitabine Use
Last Updated: 09/10/2025
SUMMARY
- INLEXZO (gemcitabine intravesical system) is an intravesical drug releasing system (iDRS), referred to as TAR-200 in literature.1
- No prospective, randomized trials have been reported to evaluate the efficacy and safety of INLEXZO in patients with prior intravesical gemcitabine use.
Product labeling
- INLEXZO (gemcitabine intravesical system) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INLEXZO-pi.pdf.
- INLEXZO (gemcitabine intravesical system) [Instructions for Use]. Horsham, PA: Janssen Biotech, Inc; https://www.janssenlabels.com/package-insert/product-instructions-for-use/INLEXZO-ifu.pdf.
Literature Search
A literature search of MEDLINE®
References
| 1 | Daneshmand S, Van der Heijden MS, Jacob JM, et al. TAR-200 for Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. [published online ahead of print July 30, 2025]. J Clin Oncol. doi:10.1200/jco-25-01651. |